Advertisement

Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis

  • Chun-Yan Cheng
  • Yi-Xin Zhang
  • Gentian Denas
  • Yao Du
  • Zhi-Cheng Jing
  • Vittorio PengoEmail author
IM - ORIGINAL

Abstract

How thrombophilia may contribute to the development of chronic thromboembolic pulmonary hypertension (CTEPH) is unknown. We searched on PubMed and EMBASE (until 15 April 2018), studies on CTEPH reporting data on inherited or acquired thrombophilia. Starting from 367 articles mentioning the search terms, 347 were excluded mainly as duplicate articles or articles not in English. After reading the full text of remaining articles, ten were excluded for being reviews, editorials, letters or case reports, and two were further removed from the analysis because of the potential selection bias. All the eight considered studies provided the proportion of patients positive for antiphospholipid (aPL) antibodies. The crude rate of aPL in CTPEH patients is 11.8% (95% CI 10.09–13.8%). The meta-analysis considering the weighted mean proportion and 95% confidence intervals (CIs) yields a rate of aPL antibody-positive profile of 12.06% (95% CI 8.12–16.65%) among the patients with CTEPH in the random effects model (I2 76.33%; 95% CI 52.75–88.14%, p = 0.0001). The sensibility analysis confirms the result. No predictors of heterogeneity are found in a meta-regression analysis. Our results suggest that aPL antibodies are frequently associated with CTEPH underlining the need to test for aPL antibodies in young patients with “idiopathic” and “provoked” PE caused by mild provoking risk factors.

Keywords

Inherited thrombophilia Antiphospholipid antibodies Chronic thromboembolic pulmonary hypertension 

Notes

Acknowledgements

Supported by CAMS Innovation Fund for Medical Sciences (2017-I2M-B&R-02). Capital Characteristic Clinic Project of Beijing Municipal (Z181100001718203). National Science Fund for Distinguished Young Scholars (81425002). The funding sources had no role in the study design, data selection and analysis, quality assessment, data synthesis and interpretation, or the decision to prepare and submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statements on human and animal rights

The procedures followed in this study are in accordance with the ethical standards and to our knowledge, no unethical study was included in the meta-analysis. Aggregate data (meta-analyses) are likely to have the same objectives as the original studies.

Informed consent

There is no particular ethical problem regarding the original informed consent of patients.

References

  1. 1.
    Simonneau G, Torbicki A, Dorfmuller P, Kim N (2017) The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 26:143.  https://doi.org/10.1183/16000617.0112-2016 CrossRefGoogle Scholar
  2. 2.
    Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E (2013) Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D92–D99.  https://doi.org/10.1016/j.jacc.2013.10.024 CrossRefGoogle Scholar
  3. 3.
    Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113(16):2011–2020.  https://doi.org/10.1161/CIRCULATIONAHA.105.602565 CrossRefGoogle Scholar
  4. 4.
    Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P, Thromboembolic Pulmonary Hypertension Study G (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2264.  https://doi.org/10.1056/nejmoa032274 CrossRefGoogle Scholar
  5. 5.
    Sacks RS, Remillard CV, Agange N, Auger WR, Thistlethwaite PA, Yuan JX (2006) Molecular biology of chronic thromboembolic pulmonary hypertension. Semin Thorac Cardiovasc Surg 18(3):265–276.  https://doi.org/10.1053/j.semtcvs.2006.09.004 CrossRefGoogle Scholar
  6. 6.
    Wagenvoort CA (1995) Pathology of pulmonary thromboembolism. Chest 107(1 Suppl):10S–17SCrossRefGoogle Scholar
  7. 7.
    Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D’Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barbera JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jais X, Simonneau G (2011) Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124(18):1973–1981.  https://doi.org/10.1161/CIRCULATIONAHA.110.015008 CrossRefGoogle Scholar
  8. 8.
    Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I (2005) Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 93(3):512–516.  https://doi.org/10.1160/TH04-10-0657 CrossRefGoogle Scholar
  9. 9.
    Khan S, Dickerman JD (2006) Hereditary thrombophilia. Thromb J 4:15.  https://doi.org/10.1186/1477-9560-4-15 CrossRefGoogle Scholar
  10. 10.
    Haythe J (2012) Chronic thromboembolic pulmonary hypertension: a review of current practice. Prog Cardiovasc Dis 55(2):134–143.  https://doi.org/10.1016/j.pcad.2012.07.005 CrossRefGoogle Scholar
  11. 11.
    Morange PE, Suchon P, Tregouet DA (2015) Genetics of venous thrombosis: update in 2015. Thromb Haemost 114(5):910–919.  https://doi.org/10.1160/TH15-05-0410 Google Scholar
  12. 12.
    European Society of Cardiology (2000) Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism. Eur Heart J 21(16):1301–1336.  https://doi.org/10.1053/euhj.2000.2250 CrossRefGoogle Scholar
  13. 13.
    Feinbloom D, Bauer KA (2005) Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 25(10):2043–2053.  https://doi.org/10.1161/01.ATV.0000181762.31694.da CrossRefGoogle Scholar
  14. 14.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.  https://doi.org/10.1136/bmj.b2535 CrossRefGoogle Scholar
  15. 15.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097.  https://doi.org/10.1371/journal.pmed.1000097 CrossRefGoogle Scholar
  16. 16.
    Park SY, Lee SM, Shin JW, Choi BW, Kim H, Lee JS, Lee SD, Park SS, Moon HS, Park YB (2016) Epidemiology of chronic thromboembolic pulmonary hypertension in Korea: results from the Korean registry. Korean J Intern Med 31(2):305–312.  https://doi.org/10.3904/kjim.2014.122 CrossRefGoogle Scholar
  17. 17.
    D’Armini AM, Totaro P, Nicolardi S, Morsolini M, Silvaggio G, Toscano F, Toscano M, Vigano M (2010) Impact of high titre of antiphospholipid antibodies on postoperative outcome following pulmonary endarterectomy. Interact Cardiovasc Thorac Surg 10(3):418–422.  https://doi.org/10.1510/icvts.2009.221630 CrossRefGoogle Scholar
  18. 18.
    Wong CL, Szydlo R, Gibbs S, Laffan M (2010) Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension. Blood Coagul Fibrinolysis 21(3):201–206.  https://doi.org/10.1097/MBC.0b013e328331e664 CrossRefGoogle Scholar
  19. 19.
    Sompradeekul S, Minipan M (2010) Clinical features and management of chronic thromboembolic pulmonary hypertension in Thai. J Med Assoc Thai 93(Suppl 1):S79–S85Google Scholar
  20. 20.
    Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G (2000) Thrombotic risk factors in pulmonary hypertension. Eur Respir J 15(2):395–399CrossRefGoogle Scholar
  21. 21.
    Auger WR, Permpikul P, Moser KM (1995) Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. Am J Med 99(4):392–396CrossRefGoogle Scholar
  22. 22.
    Simonneau G, Azarian R, Brenot F, Dartevelle PG, Musset D, Duroux P (1995) Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. Chest 107(1 Suppl):52S–55SCrossRefGoogle Scholar
  23. 23.
    Lane DA, Kunz G, Olds RJ, Thein SL (1996) Molecular genetics of antithrombin deficiency. Blood Rev 10(2):59–74CrossRefGoogle Scholar
  24. 24.
    Egeberg O (1965) Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13:516–530CrossRefGoogle Scholar
  25. 25.
    Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E, Di Minno G (2000) Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 118(5):1405–1411CrossRefGoogle Scholar
  26. 26.
    Cohoon KP, Heit JA (2014) Inherited and secondary thrombophilia. Circulation 129(2):254–257.  https://doi.org/10.1161/CIRCULATIONAHA.113.001943 CrossRefGoogle Scholar
  27. 27.
    Cervera R (2017) Antiphospholipid syndrome. Thromb Res 151(Suppl 1):S43–S47.  https://doi.org/10.1016/S0049-3848(17)30066-X CrossRefGoogle Scholar
  28. 28.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306.  https://doi.org/10.1111/j.1538-7836.2006.01753.x CrossRefGoogle Scholar
  29. 29.
    Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242.  https://doi.org/10.1111/j.1538-7836.2009.03674.x CrossRefGoogle Scholar
  30. 30.
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340(12):901–907.  https://doi.org/10.1056/NEJM199903253401201 CrossRefGoogle Scholar
  31. 31.
    Garcia D, Akl EA, Carr R, Kearon C (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122(5):817–824.  https://doi.org/10.1182/blood-2013-04-496257 CrossRefGoogle Scholar
  32. 32.
    Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V (2015) Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 14(3):214–222.  https://doi.org/10.1016/j.autrev.2014.11.003 CrossRefGoogle Scholar
  33. 33.
    Parthvi R, Sikachi RR, Agrawal A, Adial A, Vulisha A, Khanijo S, Talwar A (2017) Pulmonary hypertension associated with antiphospholipid antibody: call for a screening tool? Intractable Rare Dis Res 6(3):163–171.  https://doi.org/10.5582/irdr.2017.01044 CrossRefGoogle Scholar
  34. 34.
    Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, Simkova I, Martischnig AM, Dudczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM (2009) Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33(2):325–331.  https://doi.org/10.1183/09031936.00087608 CrossRefGoogle Scholar
  35. 35.
    Moser KM, Auger WR, Fedullo PF (1990) Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 81(6):1735–1743CrossRefGoogle Scholar
  36. 36.
    Laczika K, Lang IM, Quehenberger P, Mannhalter C, Muhm M, Klepetko W, Kyrle PA (2002) Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. Chest 121(1):286–289CrossRefGoogle Scholar
  37. 37.
    Yang S, Yang Y, Zhai Z, Kuang T, Gong J, Zhang S, Zhu J, Liang L, Shen YH, Wang C (2015) Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis 7(11):1927–1938.  https://doi.org/10.3978/j.issn.2072-1439.2015.11.43 Google Scholar
  38. 38.
    van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC (2012) Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 120(5):933–946.  https://doi.org/10.1182/blood-2012-02-407551 CrossRefGoogle Scholar
  39. 39.
    Cosmi B, Legnani C, Pengo V, Ghirarduzzi A, Testa S, Poli D, Prisco D, Tripodi A, Palareti G, Investigators P (2013) The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thromb Haemost 109(3):510–516.  https://doi.org/10.1160/TH12-01-0041 CrossRefGoogle Scholar
  40. 40.
    Lang IM, Klepetko W, Pabinger I (1996) No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH). Thromb Haemost 76(3):476–477Google Scholar
  41. 41.
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the S, Standardisation Committee of the International Society on T, Haemostasis (2009) Update of the guidelines for lupus anticoagulant detection Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7(10):1737–1740.  https://doi.org/10.1111/j.1538-7836.2009.03555.x CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Cardiology Clinic, Thrombosis Centre, Department of Cardiac Thoracic and Vascular SciencesUniversity of PaduaPaduaItaly
  2. 2.Key Laboratory of Pulmonary Vascular Medicine & FuWai Hospital, State Key Laboratory of Cardiovascular DiseaseChinese Academy Medical Sciences & Peking Union Medical CollegeBeijingPeople’s Republic of China

Personalised recommendations